CE Mark Clears In-Ear EEG Wearable for Multi-Month Home Monitoring

Cebreo Medical has received CE marking for NeuroBuds, an in-ear EEG (electroencephalography, the recording of the brain's electrical activity) wearable cleared for unassisted home monitoring lasting up to three months. The clearance opens the European market to a device the company says can run multi-day and multi-night recordings without a technician, replacing a workflow that currently depends on caps of electrodes applied by trained staff.

The device resembles a hearing aid, a deliberate design choice intended to reduce the stigma and burden attached to conventional long-term EEG monitoring. Patients position it themselves at home. The device supports monitoring periods of up to three months, with repeat measurements, so clinicians can capture brain activity across a patient's ordinary daily environment rather than a single night in a sleep laboratory.

"With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients' own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring and strengthen treatment decisions compared with conventional brain monitoring," says Rasmus Madsen, PhD, CEO of Cebreo Medical, in a release.

Where does the clinical case stand?

Extended ambulatory EEG monitoring spans sleep medicine, epilepsy, and other areas of neurophysiological research. For patients with drug-resistant epilepsy — epilepsy that does not respond to medication — the clinical need is longitudinal data: seizure counts over weeks, not snapshots.

"For patients with drug-resistant epilepsy, the question is not whether they have seizures — it's how often, and whether a new treatment is actually working. Patient-reported seizure counts are often unreliable, particularly for subtle or nocturnal seizures patients don't even notice. An ambulatory ear-EEG device that can run for weeks at a time, in the patient's own daily life, provides the EEG data with the potential to objectively quantify the seizure burden, and hence, more properly evaluate treatment," says Sandor Beniczky, MD, PhD, professor at the department of clinical neurophysiology at Rigshospitalet and the Danish Epilepsy Centre, in a release.

His framing points to the practical problem the device addresses. A patient who sleeps through a nocturnal seizure cannot report it. Diary-based seizure counts, the current default for tracking treatment response between clinic visits, miss those events entirely. An objective, weeks-long recording would give clinicians a measured baseline against which to judge whether a new therapy is working.

Note what has been cleared and what has not. The CE mark covers the device for the European market. The claims about cost reduction and stronger treatment decisions rest on the mechanism — continuous data in place of patient recall — and both quotes frame them as potential, not as demonstrated outcomes. The announcement carries no trial results, sample sizes, or head-to-head comparison with conventional EEG.

What happens next?

Following the CE marking, Cebreo Medical plans to expand commercial availability across European research and clinical sites while advancing its US regulatory pathway. For R&D managers in sleep diagnostics and neurophysiology, the clearance adds a second entry to a market that is already moving: the FDA has cleared Zeto's New Wave device for outpatient routine EEG, and sleep laboratories are weighing wireless EEG options alongside traditional leadwire systems.

The company's near-term roadmap is therefore twofold: scale European deployment into research and clinical sites, and pursue US clearance.